Botulinum toxin for the treatment of myofascial pain syndromes involving the neck and back: A review from a clinical perspective

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Climent, José M ^a   Kuan, Ta Shen ^b   Fenollosa, Pedro ^c   Martin Del Rosario, Francisco ^d  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; PLACEBO;

ANALGESIA; ANALGESIC ACTIVITY; ANTINOCICEPTION; BACKACHE; DOSE RESPONSE; DRUG EFFICACY; FOLLOW UP; HUMAN; INJECTION; MYOFASCIAL PAIN; NECK PAIN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TRAPEZIUS MUSCLE; TREATMENT RESPONSE;

EID: 84874857301     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/381459     Document Type: Review

References (77)

1. Simons D. G., Review of enigmatic MTrPs as a common cause of enigmatic musculoskeletal pain and dysfunction. Journal of Electromyography and Kinesiology 2004 14 1 95 107 2-s2.0-0842284393 10.1016/j.jelekin.2003.09.018 (Pubitemid 38169110)
2. Sluka K. A., Kalra A., Moore S. A., Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia. Muscle & Nerve 2001 24 1 37 46 (Pubitemid 32038025)
3. Gerwin R. D., Dommerholt J., Shah J. P., An expansion of Simons' integrated hypothesis of trigger point formation. Current pain and headache reports 2004 8 6 468 475 2-s2.0-16544382443
4. Kuan T. S., Chang Y. C., Hong C. Z., Distribution of active loci in rat skeletal muscle. Journal of Musculoskeletal Pain 1999 7 4 45 54 2-s2.0-0033388101
5. Hong C. Z., New trends in myofascial pain syndrome. Chinese Medical Journal 2002 65 11 501 512 2-s2.0-0036874149
6. Simons D. G., Hong C. Z., Simons L. S., Endplate potentials are common to midfiber myofacial trigger points. American Journal of Physical Medicine and Rehabilitation 2002 81 3 212 222 2-s2.0-0036183848 10.1097/00002060-200203000- 00010 (Pubitemid 34188763)
7. Hong C. Z., Simons D. G., Pathophysiologic and electrophysiologic mechanisms of myofascial trigger points. Archives of Physical Medicine and Rehabilitation 1998 79 7 863 872 2-s2.0-0031855592 10.1016/S0003-9993(98)90371-9 (Pubitemid 28322154)
8. Shah J. P., Phillips T. M., Danoff J. V., Gerber L. H., An in vivo microanalytical technique for measuring the local biochemical milieu of human skeletal muscle. Journal of Applied Physiology 2005 99 5 1977 1984 2-s2.0-26444595334 10.1152/japplphysiol.00419.2005 (Pubitemid 41547200)
9. Shah J. P., Danoff J. V., Desai M. J., Parikh S., Nakamura L. Y., Phillips T. M., Gerber L. H., Biochemicals associated with pain and inflammation are elevated in sites near to and remote from active myofascial trigger points. Archives of Physical Medicine and Rehabilitation 2008 89 1 16 23 2-s2.0-37349017629 10.1016/j.apmr.2007.10.018 (Pubitemid 350299018)
10. Mense S., Muscle pain: mechanisms and clinical significance. Deutsches Arzteblatt 2008 105 12 214 219 2-s2.0-41749104013 10.3238/artzebl.2008.0214 (Pubitemid 351487273)
11. Watkins L. R., Hutchinson M. R., Ledeboer A., Wieseler-Frank J., Milligan E. D., Maier S. F., Glia as the bad guys: implications for improving clinical pain control and the clinical utility of opioids. Brain, Behavior, and Immunity 2007 21 2 131 146 2-s2.0-33845945382 10.1016/j.bbi.2006.10.011 (Pubitemid 46038918)
12. Brin M. F., Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle and Nerve 1997 20 supplement 6 S146 S168 2-s2.0-33748271738
13. Costa J., Espírito-Santo C., Borges A., Ferreira J. J., Coelho M., Moore P., Sampaio C., Botulinum toxin type A therapy for cervical dystonia. Cochrane Database of Systematic Reviews 2005 1 CD003633 2-s2.0-18944375202
14. Dolly J. O., Aoki K. R., The structure and mode of action of different botulinum toxins. European Journal of Neurology 2006 13 supplement 4 1 9 2-s2.0-33750969100 10.1111/j.1468-1331.2006.01648.x (Pubitemid 44748278)
15. Lacy D. B., Stevens R. C., Sequence homology and structural analysis of the clostridial neurotoxins. Journal of Molecular Biology 1999 291 5 1091 1104 2-s2.0-0033520494 10.1006/jmbi.1999.2945 (Pubitemid 29423772)
16. Aikawa Y., Lynch K. L., Boswell K. L., Martin T. F. J., A second SNARE role for exocytic SNAP25 in endosome fusion. Molecular Biology of the Cell 2006 17 5 2113 2124 2-s2.0-33745758070 10.1091/mbc.E06-01-0074 (Pubitemid 44011728)
17. Simpson L. L., Maksymowych A. B., Hao S., The role of zinc binding in the biological activity of botulinum toxin. The Journal of Biological Chemistry 2001 276 29 27034 27041 2-s2.0-0035920221 10.1074/jbc.M102172200
18. Brunger A. T., Rummel A., Receptor and substrate interactions of clostridial neurotoxins. Toxicon 2009 54 5 550 560 2-s2.0-68949179783 10.1016/j.toxicon.2008.12.027
19. Mense S., Neurobiological basis for the use of botulinum toxin in pain therapy. Journal of Neurology, Supplement 2004 251 supplement 1 I1 I7 2-s2.0-1542344497
20. Kuan T. S., Chen J. T., Chen S. M., Chien C. H., Hong C. Z., Effect of botulinum toxin on endplate noise in myofascial trigger spots of rabbit skeletal muscle. American Journal of Physical Medicine and Rehabilitation 2002 81 7 512 520 2-s2.0-0036081080 10.1097/00002060-200207000-00008 (Pubitemid 34665885)
21. Aoki K. R., Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. NeuroToxicology 2005 26 5 785 793 2-s2.0-26444469528 10.1016/j.neuro.2005.01.017 (Pubitemid 41427518)
22. Jabbari B., Botulinum neurotoxins in the treatment of refractory pain. Nature Clinical Practice Neurology 2008 4 12 676 685 2-s2.0-57249084772 10.1038/ncpneuro0948
23. Aoki K. R., Francis J., Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism and Related Disorders 2011 17 supplement 1 S28 S33
24. Gazerani P., Staahl C., Drewes A. M., Arendt-Nielsen L., The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 2006 122 3 315 325 2-s2.0-33745000127 10.1016/j.pain.2006.04.014 (Pubitemid 44250975)
25. Cheshire W. P., Abashian S. W., Mann J. D., Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994 59 1 65 69 2-s2.0-0028148918 10.1016/0304-3959(94)90048-5 (Pubitemid 24311170)
26. Ernberg M., Hedenberg-Magnusson B., List T., Svensson P., Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: a randomized, controlled, double-blind multicenter study. Pain 2011 152 9 1988 1996
27. De Andrés J., Adsuara V. M., Palmisani S., Villanueva V., López-Alarcón M. D., A double-blind, controlled, randomized trial to evaluate the efficacy of botulinum toxin for the treatment of lumbar myofascial pain in humans. Regional Anesthesia and Pain Medicine 2010 35 3 255 260 2-s2.0-77952340610 10.1097/AAP.0b013e3181d23241
28. Gül K., Onal A. S., Comparison of non-invasive and invasive techniques in the treatment of patients with myofascial pain syndrome. Agri 2009 21 3 104 112 2-s2.0-70249145430
29. De Venancio R. A., Alencar F. G. P., Zamperini C., Botulinum toxin, lidocaine, and dry-needling injections in patients with myofascial pain and headaches. Cranio 2009 27 1 46 53 2-s2.0-59449091776
30. Harden R. N., Cottrill J., Gagnon C. M., Smitherman T. A., Weinland S. R., Tann B., Joseph P., Lee T. S., Houle T. T., Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: a randomized, double-blind, placebo-controlled pilot study. Headache 2009 49 5 732 743 2-s2.0-65449155562 10.1111/j.1526-4610.2008.01286.x
31. Braker C., Yariv S., Adler R., Badarny S., Eisenberg E., The analgesic effect of botulinum-toxin A on postwhiplash neck pain. Clinical Journal of Pain 2008 24 1 5 10 2-s2.0-38049009103 10.1097/AJP.0b013e318156d90c
32. Lew H. L., Lee E. H., Castaneda A., Klima R., Date E., Therapeutic use of Botulinum Toxin Type A in treating neck and upper-back pain of Myofascial Origin: a pilot study. Archives of Physical Medicine and Rehabilitation 2008 89 1 75 80 2-s2.0-37349026947 10.1016/j.apmr.2007.08.133 (Pubitemid 350299010)
33. Qerama E., Fuglsang-Frederiksen A., Kasch H., Bach F. W., Jensen T. S., A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology 2006 67 2 241 245 2-s2.0-33747065291 10.1212/01.wnl.0000224731.06168. df (Pubitemid 44305406)
34. Göbel H., Heinze A., Reichel G., Hefter H., Benecke R., Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study. Pain 2006 125 1-2 82 88 2-s2.0-33749336954 10.1016/j.pain.2006.05.001 (Pubitemid 44498966)
35. Ojala T., Arokoski J. P. A., Partanen J., The effect of small doses of botulinum toxin A on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial. Clinical Journal of Pain 2006 22 1 90 96 2-s2.0-33644915866 10.1097/01.ajp.0000151871.51406.c3 (Pubitemid 44378566)
36. Graboski C. L., Shaun Gray D., Burnham R. S., Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: a randomised double blind crossover study. Pain 2005 118 1-2 170 175 2-s2.0-27644439096 10.1016/j.pain.2005.08.012 (Pubitemid 41566596)
37. Ferrante F. M., Bearn L., Rothrock R., King L., Evidence against trigger point injection technique for the treatment of cervicothoracic myofascial pain with botulinum toxin type A. Anesthesiology 2005 103 2 377 383 2-s2.0-23044471820 10.1097/00000542-200508000-00021 (Pubitemid 41076735)
38. Kamanli A., Kaya A., Ardicoglu O., Ozgocmen S., Zengin F. O., Bayik Y., Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatology International 2005 25 8 604 611 2-s2.0-26244457818 10.1007/s00296-004-0485-6 (Pubitemid 41414058)
39. Lang A. M., Botulinum Toxin Type B in Piriformis Syndrome. American Journal of Physical Medicine and Rehabilitation 2004 83 3 198 202 2-s2.0-1242337476 10.1097/01.PHM.0000113404.35647.D8 (Pubitemid 38230671)
40. De Andrés J., Cerda-Olmedo G., Valía J. C., Monsalve V., Lopez-Alarcón, Minguez A., Use of botulinum toxin in the treatment of chronic myofascial pain. Clinical Journal of Pain 2003 19 4 269 275 2-s2.0-0038002135 10.1097/00002508-200307000-00011 (Pubitemid 36828742)
41. Foster L., Clapp L., Erickson M., Jabbari B., Botulinum toxin A and chronic low back pain a randomized, double-blind study. Neurology 2001 56 10 1290 1293 2-s2.0-0035933051 (Pubitemid 32455285)
42. Fishman L. M., Anderson C., Rosner B., BOTOX and physical therapy in the treatment of piriformis syndrome. American Journal of Physical Medicine and Rehabilitation 2002 81 12 936 942 2-s2.0-0036890417 10.1097/00002060-200212000- 00009 (Pubitemid 35351102)
43. Porta M., A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain 2000 85 1-2 101 105 2-s2.0-0033975803 10.1016/S0304-3959(99)00264-X (Pubitemid 30110749)
44. Wheeler A. H., Goolkasian P., Gretz S. S., A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 1998 23 15 1662 1667 2-s2.0-0032143946 10.1097/00007632-199808010-00009 (Pubitemid 28433865)
45. Gerwin R., Botulinum toxin treatment of myofascial pain: a critical review of the literature. Current Pain and Headache Reports 2012 16 5 413 422
46. Soares A., Andriolo R. B., Atallah A. N., Da Silva E. M. K., Botulinum toxin for myofascial pain syndromes in adults. Cochrane Database of Systematic Reviews 2009 4 CD007533
47. Zhang T., Adatia A., Zarin W., Moitri M., Vijenthira A., Chu R., Thabane L., Kean W., The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis. Inflammopharmacology 2011 19 1 21 34 2-s2.0-79951810851 10.1007/s10787-010-0069- x
48. Qerama E., Fuglsang-Frederiksen A., Jensen T. S., The role of botulinum toxin inmanagement of pain: an evidence-based review. Current Opinion in Anesthesiology 2010 23 5 602 610
49. Colhado O. C., Boeing M., Ortega L. B., Botulinum toxin in pain treatment. Revista Brasileira de Anestesiologia 2009 59 3 366 381
50. Ho K. Y., Tan K. H., Botulinum toxin A for myofascial trigger point injection: a qualitative systematic review. European Journal of Pain 2007 11 5 519 527 2-s2.0-34247611503 10.1016/j.ejpain.2006.09.002 (Pubitemid 46670781)
51. Pereda C. A., Usón Jaeger J., Carmona L., Systematic review: can botulinum toxin be recommended as treatment for pain in myofascial syndrome? Reumatologia Clinica 2006 2 4 173 182 2-s2.0-33748750261 10.1016/S1699-258X(06) 73043-1 (Pubitemid 44400053)
52. Reilich P., Fheodoroff K., Kern U., Mense S., Seddigh S., Wissel J., Pongratz D., Consensus statement: botulinum toxin in myofacial pain. Journal of Neurology 2004 251 supplement 1 I36 I38 2-s2.0-1542314419
53. Lang A. M., Botulinum toxin type A therapy in chronic pain disorders. Archives of Physical Medicine and Rehabilitation 2003 84 3, Supplement 1 S69 S73 (Pubitemid 36297761)
54. Langevin P., Peloso P. M., Lowcock J., Nolan M., Weber J., Gross A., Roberts J., Goldsmith C. H., Graham N., Burnie S. J., Haines T., Botulinum toxin for subacute/chronic neck pain. Cochrane Database of Systematic Reviews 2011 7 CD008626 2-s2.0-79961004661
55. Waseem Z., Boulias C., Gordon A., Ismail F., Sheean G., Furlan A. D., Botulinum toxin injections for low-back pain and sciatica. Cochrane Database of Systematic Reviews 2011 1 CD008257 2-s2.0-79952254377
56. Jabbari B., Machado D., Treatment of refractory pain with botulinum toxins-an evidence-based review. Pain Medication 2011 12 11 1594 1606
57. Naumann M., So Y., Argoff C. E., Childers M. K., Dykstra D. D., Gronseth G. S., Jabbari B., Kaufmann H. C., Schurch B., Silberstein S. D., Simpson D. M., Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008 70 19 1707 1714 2-s2.0-43149084857 10.1212/01.wnl.0000311390.87642.d8 (Pubitemid 351644139)
58. Scott N. A., Guo B., Barton P. M., Gerwin R. D., Trigger point injections for chronic non-malignant musculoskeletal pain: a systematic review. Pain Medicine 2009 10 1 54 69 2-s2.0-59649110656 10.1111/j.1526-4637.2008.00526.x
59. Ferreira J. J., Couto M., Costa J., Coelho M., Rosa M. M., Sampaio C., Botulinum toxin for the treatment of pain syndromes. Acta reumatológica portuguesa 2006 31 1 49 62 2-s2.0-34447546438
60. Gerwin R. D., Shannon S., Hong C. Z., Hubbard D., Gevirtz R., Interrater reliability in myofascial trigger point examination. Pain 1997 69 1-2 65 73 2-s2.0-0031049390 10.1016/S0304-3959(96)03248-4 (Pubitemid 27081409)
61. Sikdar S., Shah J. P., Gebreab T., Yen R., Gilliams E., Danoff J., Gerber L. H., Novel applications of ultrasound technology to visualize and characterize myofascial trigger points (MTrPs) and surrounding soft tissue. Archives of Physical Medicine and Rehabilitation 2009 90 1829 1838
62. Tough E. A., White A. R., Richards S., Campbell J., Variability of criteria used to diagnose myofascial trigger point pain syndrome-evidence from a review of the literature. Clinical Journal of Pain 2007 23 3 278 286 2-s2.0-33847260255 10.1097/AJP.0b013e31802fda7c
63. Hou C. R., Tsai L. C., Cheng K. F., Chung K. C., Hong C. Z., Immediate effects of various physical therapeutic modalities on cervical myofascial pain and trigger-point sensitivity. Archives of Physical Medicine and Rehabilitation 2002 83 10 1406 1414 2-s2.0-0036792686 10.1053/apmr.2002.34834
64. Gerwin R. D., Classification, epidemiology, and natural history of myofascial pain syndrome. Current Pain and Headache Reports 2001 5 5 412 420 2-s2.0-0035487832
65. Freund B. J., Schwartz M., Erratum: Treatment of whiplash associated with neck pain with botulinum toxin-A: a pilot study. Journal of Rheumatology 2000 27 6 1577 2-s2.0-0034045280 (Pubitemid 30354080)
66. Shankar H., Cummings C., Ultrasound imaging of embedded shrapnel facilitates diagnosis and management of myofascial pain syndrome. Pain Practice 2012 10.1111/papr.12002
67. Jabbari B., Ney J., Sichani A., Monacci W., Foster L., Difazio M., Treatment of refractory, chronic low back pain with botulinum neurotoxin A: an open-label, pilot study. Pain Medicine 2006 7 3 260 264 2-s2.0-33646413909 10.1111/j.1526-4637.2006.00147.x (Pubitemid 43676672)
68. Hong C. Z., Lidocaine injection versus dry needling to myofascial trigger point: the importance of the local twitch response. American Journal of Physical Medicine and Rehabilitation 1994 73 4 256 263 2-s2.0-0028108839 10.1097/00002060-199407000-00006 (Pubitemid 24258793)
69. Yoon S. H., Rah U. W., Sheen S. S., Cho K. H., Comparison of 3 needle sizes for trigger point injection in myofascial pain syndrome of upper- and middle-trapezius muscle: a randomized controlled trial. Archives of Physical Medicine and Rehabilitation 2009 90 8 1332 1339 2-s2.0-67849118324 10.1016/j.apmr.2009.01.028
70. Sola A. E., Kuitert J. H., Myofascial trigger point pain in the neck and shoulder girdle. Northwest Medicine 1955 54 980 984
71. Sola A. E., Williams R. L., Myofascial pain syndromes. Neurology 1956 6 91 95
72. Frost F. A., Jessen B., Siggaard-Andersen J., A control, double-blind comparison of mepivacaine injection versus saline injection for myofascial pain. The Lancet 1980 1 8167 499 500 2-s2.0-0018876021 (Pubitemid 10176619)
73. Tfelt Hansen P., Lous I., Olesen J., Prevalence and significance of muscle tenderness during common migraine attacks. Headache 1981 21 2 49 54 2-s2.0-0019513383 (Pubitemid 11147089)
74. Lewit K., The needle effect in the relief of myofascial pain. Pain 1979 6 1 83 90 2-s2.0-0018342481 10.1016/0304-3959(79)90142-8 (Pubitemid 9103194)
75. Baldry P., Management of myofascial trigger point pain. Acupuncture in Medicine 2002 20 1 2 10 2-s2.0-0036198748 (Pubitemid 34258752)
76. Miller D., Richardson D., Eisa M., Bajwa R. J., Jabbari B., Botulinum neurotoxin-a for treatment of refractory neck pain: a randomized, double-blind study. Pain Medicine 2009 10 6 1012 1017 2-s2.0-70349479057 10.1111/j.1526-4637. 2009.00658.x
77. Jeynes L. C., Gauci C. A., Evidence for the use of botulinum toxin in the chronic pain setting-a review of the literature. Pain Practice 2008 8 4 269 276 2-s2.0-48249154202 10.1111/j.1533-2500.2008.00202.x